Tumor Volume is a Better Prognostic Factor than Greatest Tumor Diameter in Stage Ia Non-small Cell Lung Cancer

Abstract

Objective: The objective was to determine whether tumor volume, calculated by multiplying 3-dimensional diameters recorded from surgical specimens, could represent tumor size more precisely than the currently used greatest tumor diameter (T status) as a prognostic factor in early-stage non-small cell lung cancer (NSCLC). Methods: From 1991 to 2001, a total of 236 stage Ia NSCLC patients underwent curative resection in our institution. Their clinicopathological factors were retrospectively reviewed. The cases were grouped according to stereographic tumor size. Group 1 included tumor volumes less than 0.5236 (1³ × π/6) cm³, Group 2 included tumor volumes between 0.5236 - 4.1888 (2³ × π/6) cm³, while Group 3 included tumor volumes between 4.188 - 14.1372 (3³ × π/6) cm³. Overall survival and disease-free interval analyses were performed with the Kaplan-Meier method and multivariable Cox's proportional hazard model. Tumor volume and other clinico-pathological factors were included for analysis. Results: Median follow-up was 55.5 months. The overall 5- and 10-year survival rates were 78 % and 71 %, and the 5- and 10-year disease-free intervals were 68 % and 64 %, respectively. The overall survival (p = 0.0075) and disease-free interval (p = 0.0025) showed significant differences between tumor volume groups. Smoking history, presence of symptoms and the number of resected lymph nodes were also significantly related to overall survival and disease-free interval. Conclusion: The products of 3-D diameters (tumor volume) more precisely evaluated tumor size as well as survival of patients with stage Ia NSCLC.

Thoracic surgery - non-small cell lung cancer - tumor volume - tumor size

References

• 1 Wu Y C, Lin Jeff C F, Hsu W H, Huang B S, Huang M S, Wang L S. Long-term results of pathological stage I non-small cell lung cancer: validation of using the number of totally removed lymph nodes as a staging control.  Eur J Cardiothorac Surg. 2003;  24 994-1001
• 2 Gajra A, Newman N, Gamble G P, Kohman L J, Graziano S L. Effect of number of lymph nodes sampled on outcome in patients with stage I non-small cell lung cancer.  J Clin Oncol. 2003;  21 1029-1034
• 3 Port J L, Kent M S, Korst R J, Libby D, Pasmantier M, Altorki N K. Tumor size predicts survival within stage Ia non-small cell lung cancer.  Chest. 2003;  124 1828-1833
• 4 Pearson F G, Cooper J D, Deslauriers J, Ginsberg R J, Hiebert C A, Patterson G A. et al .Thoracic Surgery. Philadelphia, PA; Churchill Livingstone 2002: 820-821
• 5 Riquet M, Manac'h D, Barthes F LP, Dujon A, Debrosse D, Debesse B. Prognostic value of T and N in non small cell lung cancer three centimeters or less in diameter.  Eur J Cardiothorac Surg. 1997;  11 440-444
• 6 Koike T, Terashima M, Takizawa T, Watanabe T, Kurita Y, Yokoyama A. Clinical analysis of small sized-peripheral lung cancer.  J Thorac Cardiovasc Surg. 1998;  115 1015-1020
• 7 Harpole Jr D H, Herndon I IJE, Young Jr W G, Wolfe W G, Sabiston Jr D C. Stage I non small cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence.  Cancer. 1995;  76 787-796
• 8 Goldstein N S, Mani A, Chmielewski G, Welsh R, Pursel S. Prognostic factors in T1 N0 M0 adenocarcinomas and bronchioloalveolar carcinomas of the lung.  Am J Clin Pathol. 1999;  112 391-402
• 9 Gajra A, Newman N, Gamble G P, Abraham N Z, Kohman L J, Graziano S L. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease.  Lung Cancer. 2003;  42 51-57
• 10 Martini N, Bains M S, Burt M E, Zakowski M F, McCormack P, Rusch V W. et al . Incidence of local recurrence and second primary tumors in resected stage I lung cancer.  J Thorac Cardiovasc Surg. 1995;  109 120-129
• 11 Patz Jr E F, Rossi S, Harpole Jr D H, Herndon J E, Goodman P C. Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer.  Chest. 2000;  117 1568-1571
• 12 Yanagi S, Sugiura H, Morikawa T, Kaji M, Okushiba S, Kondo S. et al . Tumor size does not have prognostic significance in stage Ia NSCLC.  Anticancer Res. 2000;  20 1155-1168
• 13 Coakley F V, Kurhanewicz J, Lu Y, Jones K D, Swanson M G, Chang S D. et al . Prostate cancer tumor volume: measurement with endorectal MR and MR spectroscopic imaging.  Radiology. 2002;  223 91-97
• 14 Xu H X, Yin X Y, Lu M D, Liu G J, Xu Z F. Estimation of liver tumor volume using a three-dimensional ultrasound volumetric system.  Ultrasound Med Biol. 2003;  29 839-846
• 15 Usuda K, Saito Y, Kanma K, Sagawa M, Sato M, Nagamoto N. et al . Resected roentgenographically occult bronchogenic squamous cell carcinoma tumor size, survival and recurrence.  Nippon Geka Gakkai Zasshi. 1993;  94 631-636
• 16 Iwasaki A, Shirakusa T, Enatsu S, Maekawa S, Hamada T, Hamasaki M. The value of tumor volume in surgically resected non-small cell lung cancer.  Thorac Cardiov Surg. 2006;  54 112-116
• 17 Fujisawa T, Iizasa T, Saitoh Y, Sekine Y, Motohashi S I, Yasukawa T. et al . Smoking before surgery predicts poor long-term survival in patients with stage I non-small-cell lung carcinomas.  J Clin Oncol. 1999;  17 2086-2091
• 18 Hannisdal E, Engan T. Blood analysis and survival in symptom- and survey-dectected lung cancer patients.  J Intern Med. 1991;  229 337-341
• 19 Sobue T, Suzuki T, Matsuda M, Kuroishi T, Ikeda S, Naruke T. The Japanese Lung Cancer Screening Research Group . Survival for clinical stage I lung cancer not surgically treated, comparison between screen-detected and symptom-detected cases.  Cancer. 1992;  69 685-692
• 20 Patz Jr E F, Goodman P C, Bepler G. Screening for lung cancer.  New Engl J Med. 2000;  343 1627-1633